


Fibroid Uterus



Definition

Uterine fibroids (leiomyomas):

- are benign, monoclonal smooth muscle tumors of the uterus that contain varying amounts of fibrous connective tissue.
- They are the most common pelvic tumors in women, are hormonally responsive, and may be asymptomatic or associated with symptoms such as heavy menstrual bleeding, pelvic pain, and infertility.”

Pathogenesis

● Step 1: How fibroids start

- Fibroids begin from one muscle cell in the uterus wall (myometrium).
 - This cell undergoes a genetic change (mutation).
 - The most common mutation is in the MED12 gene.
 - Others include HMGA2 and some rare ones.
 - Because of this mutation, that single cell starts multiplying → forming a clonal tumor (all cells come from one parent cell).
- e hormone-dependent, benign tumors.

Pathogenesis

● Step 2: Why they grow (hormones)

- Fibroids need hormones to grow:
- Estrogen → increases the number of progesterone receptors in the fibroid.
- Progesterone → the main hormone that makes the fibroid bigger, prevents cell death, and increases fibrosis (scar-like tissue).
- That's why:
- Fibroids grow in reproductive years (high hormones).
- They shrink after menopause (low hormones).
- They enlarge in pregnancy (hormones high).

Pathogenesis

- Step 3: Growth factors & extracellular matrix (ECM)
 - Fibroid cells release growth factors like TGF- β (Transforming Growth Factor), IGF, EGF.
 - These growth factors:
 - Stimulate more cell division.
 - Stimulate fibroblasts to make collagen and fibronectin → this builds up ECM.
 - Result: fibroids feel hard, rubbery, and fibrotic.

Pathogenesis


- Step 4: Local environment & blood supply
 - Fibroids create their own mini environment:
 - Poor blood supply → relative hypoxia (low oxygen).
 - This triggers VEGF (angiogenesis factor) to form new vessels.
 - Local cytokines & inflammation keep the tumor alive and expanding.

✓ In short:

Fibroids start from a genetic change in one muscle cell, then hormones (estrogen & progesterone) feed the growth, while growth factors and fibrosis make them enlarge and hard. That's why they are hormone-dependent, benign tumors.

Types of Fibroids

Types of Fibroids



- **Subserosal leiomyoma:** located in the outer uterine wall beneath the peritoneal surface
- **Intramural leiomyoma (most common):** growing from within the myometrium wall
- **Submucosal leiomyoma:** located directly below the endometrial layer (uterine mucosa)
- **Cervical leiomyoma:** located in the cervix
- **Diffuse uterine leiomyomatosis:** The uterus is grossly enlarged due to the presence of numerous fibroids.

History

Demographic Data

- Name , Age (common in 30–50 years) , Marital status, work.

Presenting Complaints

- Menstrual symptoms
- Heavy/prolonged bleeding
- Pressure symptoms
- Urinary frequency, urgency, retention (pressure on bladder).
- Constipation
- Abdominal lump or heaviness.
- Infertility, recurrent miscarriage, preterm labor.
- Pain
- Chronic pelvic pain.
- Acute pain (red degeneration, torsion of pedunculated fibroid).

History

Past History

- Previous similar complaints.
- History of anemia, blood transfusions.

Obstetric & Gynecological History

- Menstrual history
- Obstetric history (number of pregnancies, outcomes).
- Contraceptive history.

Medical & Drug History

- Previous surgeries for fibroid or uterus.
- Diseases
- Medication

Family & Social History

- Family history of fibroids.
- Impact on quality of life (fatigue, social/sexual issues).

Smoking, Alcohol

Examination

1. General Examination

- General appearance – pallor (anemia).
- Vital signs
- BMI/obesity.
- Signs of thyroid disease or other comorbidities.

2. Abdominal Examination

- **Inspection** – lower abdominal swelling .
- **Palpation**
 - Lump arising from pelvis, firm, irregular, nodular.
 - Non-tender unless degeneration present.
 - Mobile from side to side, but restricted mobility vertically.
 - Cannot be pushed below pubic symphysis (uterine origin).
- **Percussion** – dull over lump, resonant around.
- **Auscultation** – usually silent (unless pregnancy).

Examination


3. Pelvic Examination

- **Speculum:** Cervix may be pulled up, irregular, or distorted.
- **Bimanual palpation:**
 - Uterus enlarged, firm, irregular surface.
 - Mass continuous with uterus.
 - Mobility: mass moves with cervix.

4. Rectovaginal Examination

- To assess posterior fibroids and rectal involvement.

Differential diagnosis of uterine leiomyoma



Adenomyosis

- Definition:
 - Benign smooth muscle tumors within the uterine wall
 - (submucous, subserous, or in myometrium)
- Risk factor: Early menarche, Nullipara
- Clinical features:
 - Dysmenorrhea
 - Abnormal bleeding
 - Infertility (difficulty conceiving and increased risk of pregnancy loss)
- Uterine findings: Irregularly enlarged, firm
- Pathology:
 - smooth muscle tissue in a whorled pattern with well-demarcated borders

Endometriosis

- Definition: Benign endometrial tissue within the uterine wall
- Risk factor: Early menarche Increased parity Previous uterine surgery
- Clinical features:
 - Dysmenorrhea
 - Abnormal bleeding
 - Menorrhagia
 - Chronic pelvic pain
- Uterine findings: Uniformly enlarged
- Pathology:
 - Irregular distribution of smooth cells and endometrial glandular tissue in the myometrium

Endometrial polyps

- Definition: Benign endometrial tissue outside the uterus
- Risk factor: Retrograde menstruation
- Clinical features:
 - Dysmenorrhea
 - Pelvic pain
 - Abnormal bleeding
 - Dyspareunia
 - Dysphasia
 - Infertility
- Uterine findings: Typically, not enlarged
- Pathology:
 - Gunshot lesions: black or yellow-brown nodules
 - Chocolate cysts

Endometrial polyps


- Definition:
 - Overgrowth of localized endometrial tissue attached to the inner wall of the uterus, usually benign
- Risk factor:
 - Menopause, Obesity, Hypertension, Tamoxifen therapy, Lynch syndrome See “Risk factors for endometrial polyps.
- Clinical features:
 - Abnormal bleeding
 - Menorrhagia
 - Postmenopausal bleeding
 - Infertility/difficulty conceive
- Uterine findings: Typically, not enlarged
- Pathology:
 - Pedunculated or sessile
 - Single or multiple
 - Length varies (up to many centimeters in size)

Uterine leiomyosarcoma


- Definition:
 - Rare malignant tumor arising from the smooth muscle cells of the myometrium
- Risk factor: Menopause & Tamoxifen use
- Clinical features:
 - Symptoms similar to uterine fibroids
 - Menstrual irregularities
 - Postmenopausal bleeding
 - Pelvic pain
- Uterine findings: Rapidly enlarging
- Pathology:
 - Single lesions with areas of coagulative necrosis and/or hemorrhage
 - Cords of polygonal cells with eosinophilic cytoplasm, abundant mitoses, and cellular atypia are common.

Pharmacotherapy for uterine leiomyoma ^[4]

Predominant symptoms	Agents	Important considerations
<u>Heavy menstrual bleeding</u> without features of <u>mass effect</u>	<ul style="list-style-type: none"> • <u>GnRH antagonists</u> in combination with <u>hormone therapy</u> ^{[15][16]} <ul style="list-style-type: none"> ◦ Elagolix/<u>estradiol/norethindrone</u> combination ◦ Or relugolix/<u>estradiol/norethindrone</u> 	<ul style="list-style-type: none"> • Use is limited to 2 years • May cause <u>menopausal</u> symptoms, increased <u>LDL</u>, and loss of <u>bone density</u>
	<ul style="list-style-type: none"> • <u>Levonorgestrel intrauterine device (IUD)</u> 	<ul style="list-style-type: none"> • Difficult insertion if <u>uterine cavity</u> is distorted • High rate of <u>IUD</u> expulsion in patients with <u>leiomyomas</u> • May be more effective than <u>oral contraceptives</u> at reducing menstrual blood loss ^[4]
	<ul style="list-style-type: none"> • <u>Oral contraceptives</u> (combined oral contraceptive pill or progesterone-only pill) 	<ul style="list-style-type: none"> • Often used as initial treatment for <u>heavy menstrual bleeding</u>
	<ul style="list-style-type: none"> • <u>Tranexamic acid</u> 	<ul style="list-style-type: none"> • Contraindicated in patients with <u>risk factors for VTE</u> ^[4]
<u>Mass effect</u> with or without <u>heavy menstrual bleeding</u>	<ul style="list-style-type: none"> • <u>GnRH agonists</u> (e.g., <u>leuprolide</u>) 	<ul style="list-style-type: none"> • Used primarily as a short-term <u>bridge therapy</u>: <ul style="list-style-type: none"> ◦ Before planned <u>surgery</u> (decreases <u>leiomyoma</u> size and vascularization and overall uterine size) ◦ Before interventional therapy or additional pharmacotherapy ◦ Until <u>menopause</u> • Not suitable as long-term therapy because of the risk of hypoestrogenic effects (e.g., <u>osteoporosis</u>, <u>hot flashes</u>, altered <u>lipid profile</u>)



Uterine leiomyomas



Pedunculated uterine fibroid

Thank You

